x min read

Watch List Highlights - Apricus Biosciences Inc (NASDAQ:APRI), Neptune Technologies & Bioresources-Ord (NASDAQ:NEPT), Pharmacyclics, Inc. (NASDAQ:PCYC)

Watch List Highlights - Apricus Biosciences Inc (NASDAQ:APRI), Neptune Technologies & Bioresources-Ord (NASDAQ:NEPT), Pharmacyclics, Inc. (NASDAQ:PCYC)
Written by
Joel Najarian
Published on
October 20, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Apricus Biosciences Inc (NASDAQ:APRI), the pharmaceutical company said it licensed the U.S. development and commercialization rights for fispemifene, a treatment for urological conditions in men, from private therapeutics firm Forendo Pharma. Based on the terms of the agreement, Forendo received an upfront license fee of $12.5 million. The agreement also includes additional potential clinical and regulatory milestone payments to Forendo of up to $45 million, including potential for FDA approval, as well as potential commercial milestone payments totaling up to $260 million, based on achieving specified annual net sales levels up to $1 billion in the U.S. Apricus Biosciences will be responsible for clinical development and future commercialization efforts of fispemifene in the U.S. Apricus Biosciences Inc (NASDAQ:APRI) will pay low double-digit royalties based on net sales once fispemifene is commercialized.Neptune Technologies & Bioresources-Ord (NASDAQ:NEPT) said Monday it has signed an exclusive, worldwide license agreement with BlueOcean Nutrascience under Neptune's composition and extraction patents covering the production and sale of marine derived oil products containing phospholipids. The license allows BlueOcean and its shrimp joint venture affiliate to produce and sell shrimp oil products extracted from three species of North Atlantic cold water shrimp in various food-related markets, including dietary ingredients and natural health products.BlueOcean will pay Neptune Technologies & Bioresources-Ord (NASDAQ:NEPT) a minimum yearly cash royalty, and a royalty per unit of product sold. As well, an initial upfront payment will be payable at closing through the issuance of BlueOcean shares. Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids.Pharmacyclics, Inc. (NASDAQ:PCYC), a clinical-stage biopharmaceutical company, said Monday that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on data from a Phase 2 study evaluating the use of IMBRUVICA (ibrutinib) in patients with Waldenstrom's macroglobulinemia (WM). WM is a slow-growing, currently incurable, rare type of B-cell lymphoma or which no established standard of care or approved therapeutic exists.IMBRUVICA is currently approved by the FDA for three indications: for the treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) who have received at least one prior therapy, and for CLL patients with a deletion of the short arm of chromosome 17 (del 17p), including treatment-naive and previously treated del 17p CLL patients. Pharmacyclics, Inc. (NASDAQ:PCYC) is trading between a 52-week range of $82.51-154.89.Accelerated approval was granted for the MCL indication based on overall response rate (ORR). Improvements in survival or disease-related symptoms have not been established. Continued approval for the MCL indication may be contingent upon verification of clinical benefit in confirmatory trials. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by PCYC and Janssen Biotech, Inc., a wholly owned subsidiary of Johnson & Johnson (JNJ).

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.